Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCaLL: Ranibizumab + Micropulse Laser for DME
NCT02059772Phase 4Unknown
- Sponsor
- GWT-TUD
- Start
- Apr 2014
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in diabetic macular edema (DME) (2 arms), sponsored by GWT-TUD. Primary endpoint: Best Corrected Visual Acuity at 12 months. Status: unknown.
02
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02059772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059772.